Annual Operating Expenses
$25.07 M
+$10.19 M+68.49%
December 31, 2023
Summary
- As of February 7, 2025, CNTX annual total operating expenses is $25.07 million, with the most recent change of +$10.19 million (+68.49%) on December 31, 2023.
- During the last 3 years, CNTX annual operating expenses has risen by +$22.50 million (+874.75%).
- CNTX annual operating expenses is now at all-time high.
Performance
CNTX Operating Expenses Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly Operating Expenses
$18.70 M
+$15.61 M+505.52%
September 1, 2024
Summary
- As of February 7, 2025, CNTX quarterly total operating expenses is $18.70 million, with the most recent change of +$15.61 million (+505.52%) on September 1, 2024.
- Over the past year, CNTX quarterly operating expenses has increased by +$15.61 million (+505.52%).
- CNTX quarterly operating expenses is now at all-time high.
Performance
CNTX Quarterly Operating Expenses Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Operating Expenses Formula
Operating Expenses = Selling, General & Administrative (SG&A) Expenses + Research & Development (R&D) Expenses + Depreciation & Amortization + Other Operating Expenses
CNTX Operating Expenses Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | +68.5% | +505.5% |
| 3 y3 years | +874.8% | +253.4% |
| 5 y5 years | +366.3% | +253.4% |
CNTX Operating Expenses Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3-year | at high | +237.1% | at high | +505.5% |
| 5 y | 5-year | at high | +874.8% | at high | +3640.3% |
| alltime | all time | at high | +874.8% | at high | +3640.3% |
Context Therapeutics Operating Expenses History
| Date | Annual | Quarterly |
|---|---|---|
| Sep 2024 | - | $18.70 M(+505.5%) |
| Jun 2024 | - | $3.09 M(-19.2%) |
| Mar 2024 | - | $3.82 M(-44.9%) |
| Dec 2023 | $25.07 M(+68.5%) | $6.93 M(+12.2%) |
| Sep 2023 | - | $6.18 M(+16.8%) |
| Jun 2023 | - | $5.29 M(-20.6%) |
| Mar 2023 | - | $6.67 M(+71.7%) |
| Dec 2022 | $14.88 M | $3.88 M(-4.1%) |
| Sep 2022 | - | $4.05 M(+15.4%) |
| Jun 2022 | - | $3.51 M(+1.9%) |
| Date | Annual | Quarterly |
|---|---|---|
| Mar 2022 | - | $3.44 M(+11.4%) |
| Dec 2021 | $7.44 M(+189.2%) | $3.09 M(+97.2%) |
| Sep 2021 | - | $1.57 M(-19.1%) |
| Jun 2021 | - | $1.94 M(+130.6%) |
| Mar 2021 | - | $840.30 K(+9.2%) |
| Dec 2020 | $2.57 M(-52.2%) | $769.50 K(+18.2%) |
| Sep 2020 | - | $651.10 K(-0.1%) |
| Jun 2020 | - | $651.60 K(+30.3%) |
| Mar 2020 | - | $500.00 K |
| Dec 2019 | $5.38 M | - |
FAQ
- What is Context Therapeutics annual total operating expenses?
- What is the all time high annual operating expenses for Context Therapeutics?
- What is Context Therapeutics annual operating expenses year-on-year change?
- What is Context Therapeutics quarterly total operating expenses?
- What is the all time high quarterly operating expenses for Context Therapeutics?
- What is Context Therapeutics quarterly operating expenses year-on-year change?
What is Context Therapeutics annual total operating expenses?
The current annual operating expenses of CNTX is $25.07 M
What is the all time high annual operating expenses for Context Therapeutics?
Context Therapeutics all-time high annual total operating expenses is $25.07 M
What is Context Therapeutics annual operating expenses year-on-year change?
Over the past year, CNTX annual total operating expenses has changed by +$10.19 M (+68.49%)
What is Context Therapeutics quarterly total operating expenses?
The current quarterly operating expenses of CNTX is $18.70 M
What is the all time high quarterly operating expenses for Context Therapeutics?
Context Therapeutics all-time high quarterly total operating expenses is $18.70 M
What is Context Therapeutics quarterly operating expenses year-on-year change?
Over the past year, CNTX quarterly total operating expenses has changed by +$15.61 M (+505.52%)